Disruptions in Aesthetic Medicine: A Global Analysis of GLP-1 Agonists Using Punctuated Equilibrium Framework

The adoption of glucagon-like peptide-1 (GLP-1) receptor agonists, such as semaglutide, has significantly improved obesity and type 2 diabetes management. However, their unintended side effects, particularly facial volume loss, termed "Ozempic face," have disrupted aesthetic medicine. This intersection between metabolic health and aesthetics raises ethical dilemmas and growing dependency on corrective interventions such as dermal fillers.

A mixed-methods approach was used, incorporating content analysis, social media sentiment analysis, and social network modeling. Data were collected from 15 peer-reviewed studies, clinical reports, and 3.79 million social media posts across global regions. Sentiment analysis identified public perceptions, whereas network analysis examined influencer dominance in promoting aesthetic solutions.

Findings revealed a 40% increase in filler consultations attributed to GLP-1-related aesthetic concerns. Sentiment analysis showed that 72% of high-engagement content was driven by influencers normalizing fillers as necessary adjuncts to GLP-1 therapies. Ethical concerns were prominent, particularly in regions such as Asia and South America, where commercial narratives dominate. In contrast, North America and Europe demonstrated a more balanced approach, prioritizing informed patient care under regulatory frameworks.

GLP-1 therapies represent a transformative shift in metabolic care but introduce significant aesthetic, ethical, and psychological challenges. Social media amplifies commercial influences, often at the cost of evidence-based practice. Regulatory reforms, longitudinal studies, and enhanced patient education are critical to navigating this evolving landscape and ensuring patient well-being.